Scopio Labs, a provider of digital cell morphology imaging solutions, has rolled out a new digital application that enables scanning and analysis of the bone marrow aspirate.

The new solution, dubbed Full-Field Bone Marrow Aspirate (FF-BMA) Application, runs on the company’s X100 and X100HT devices.

Together with full-field imaging and an AI-driven decision support system, the FF-BMA Application is said to bring digital transformation to hematopathology.

With embedded remote analysis capabilities over a secure hospital network, it can facilitate review of the aspirate from any location, lab or remote site.

In addition, the application eliminates the need for a manual microscope, and enables hospitals and labs to digitise haematology diagnostics and testing, said the company.

Scopio Labs chief product officer Amy Meitus said: “Reviewing bone marrow aspirate is an art form – it is a complex and intricate analysis predominantly performed by trained hematopathologists or haematologists.

“Scopio’s FF-BMA platform provides a digital end-to-end solution that augments physicians’ capabilities. Our AI-powered Decision Support System provides the clinician with an in-depth explanation for every suggestion offered, engendering a level of trust and transparency crucial for confident decision making.”

The bone marrow serves as a ‘blood cell factory’, where blood cells are created and reach maturation before they were transferred to the peripheral blood.

In the incident of malignancy or disease of the bone marrow, certain cell populations of blood cells are over or under-produced.

Regular bone marrow aspirates and analysis are used to detect the blood disorders, such as leukaemia, multiple myeloma, myelodysplastic syndrome and more.

Conventionally, standard bone marrow aspirate review is conducted manually through microscopic analysis of cells, with a recommended review of at least 500 cells per sample.

Scopio said that its Full-Field imaging provides a digital copy of the slide at 100X magnification while the AI-powered Decision Support System analyses thousands of cells.

It provides a complete analysis of various characteristics of the sample, including a 500-cell differential that accurately denotes the distribution of cells across the sample.

Scopio Labs co-founder and CEO Itai Hayut said: “We are excited to bring this novel and much-needed application to the market. Whereas tissue pathology has reached the digital age, hematopathology has remained analogue – until now.

“As the first digital decision support tool for bone marrow aspirate analysis, this application is creating a wave of anticipation among specialists.

“Bone marrow is the key to diagnosing certain cancers, such as leukaemia and multiple myeloma, but are notoriously complex samples to analyse.”